What Is DATROWAY? A Simple Patient Guide To Uses, Infusion, Side Effects, and What To Expect
When you’re told you may need a treatment like DATROWAY, it’s completely normal to have questions. What is it, why is it being given, how does the infusion work, and what might you experience during treatment?
In this simple guide, we’ll walk through what DATROWAY is, how it is used, what the infusion process may look like, possible side effects, and what patients commonly want to know before starting.
What Is DATROWAY In Simple Words?
DATROWAY (datopotamab deruxtecan / Dato-DXd) is a type of targeted cancer treatment called an antibody-drug conjugate (ADC).1
It is designed to target TROP-2 (Trophoblast cell surface antigen 2), a protein found in high amounts on many cancer cells, including some breast, lung, cervical, colorectal, esophageal, and gastric cancers.1
How DATROWAY Works Against Cancer Cells?
DATROWAY targets TROP-2, which is linked to cancer growth, spread, and survival through signalling pathways such as PI3K/Akt, MAPK/ERK, JAK/STAT, TGFβ, and WNT/β-catenin.
It uses a humanized anti-TROP-2 IgG1 monoclonal antibody to find and attach to these cancer cells. It then delivers a topoisomerase I inhibitor directly into the cell through a cleavable linker. This approach helps send the anti-cancer drug to tumor cells while aiming to reduce damage to healthy tissues.1
Which Cancers Is DATROWAY Used For?
DATROWAY is used in certain advanced solid tumors that show the TROP-2 protein, a target found in many cancers. It has been approved for unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- breast cancer).1
Clinical studies are also evaluating its use in other cancers, including:1
- Non-small cell lung cancer (NSCLC)
- Urothelial tract cancer
- Ovarian cancer
- Endometrial cancer
TROP-2 is commonly overexpressed in several epithelial cancers, such as breast, lung, cervical, colorectal, esophageal, and gastric cancers, which is why it is an important treatment target.1
Why Doctors May Recommend DATROWAY After Other Treatments
Research showed that DATROWAY (Dato-DXd) was studied in patients with heavily pretreated advanced breast cancer, including HR+/HER2– breast cancer and triple-negative breast cancer (TNBC). Even after multiple previous treatments, DATROWAY showed encouraging antitumor activity, with confirmed responses seen in both groups:2
- 8% in HR+/HER2– BC
- 8% in TNBC
Some responses were also durable, meaning they lasted for a meaningful period of time.2
Because of these results, doctors may consider DATROWAY for patients whose cancer has already been treated with other therapies, especially when additional treatment options are needed.
What To Expect Before Starting DATROWAY
Before starting DATROWAY, your doctor will ask about your overall health and current medicines. Be sure to tell your doctor or pharmacist if you have:3
- Any allergies to this medicine, its ingredients, or other drugs, foods, or substances
- Any prescription medicines, over-the-counter medicines, vitamins, supplements, or herbal products you take
- Breathing or lung conditions such as asthma, COPD, or emphysema
- Corneal disease or other eye problems
- Kidney disease or liver disease
If you wear contact lenses, you may be told to avoid using them during treatment.3
Your doctor will also discuss pregnancy and breastfeeding safety:3
- A pregnancy test may be needed before treatment starts
- Pregnancy should be avoided during treatment
How DATROWAY Is Given
DATROWAY comes as a powder mixed with liquid and is given as an intravenous infusion (IV infusion) into a vein by a healthcare provider in a hospital or clinic. Other medicines may be given to help prevent or manage infusion reactions. Your doctor may also slow, delay, or stop treatment if side effects occur.3
What Happens On Infusion Day
DATROWAY is given in a hospital or clinic by a doctor or nurse experienced in cancer treatment. The recommended dose is 6 mg per kilogram of body weight every 3 weeks. Your care team calculates the exact dose based on your weight.
The first infusion is given over 90 minutes. If it is well tolerated, later infusions may be given over 30 minutes. After each infusion, you will be monitored for 30 minutes for side effects.4
Before treatment, your doctor or nurse may give premedication to help prevent infusion-related reactions, such as an antihistamine and paracetamol, with or without glucocorticoids. Medicines to help prevent nausea and vomiting may also be used, including dexamethasone, 5-HT3 antagonists, or NK1 receptor antagonists.
During treatment, your team may also recommend mouthwash to help prevent mouth sores and preservative-free lubricating eye drops. If side effects occur, the infusion may be slowed, interrupted, the dose lowered, or treatment stopped.4
How Often DATROWAY Is Usually Given
It is usually given once every 3 weeks. Your doctor will decide how many infusions you need. After the first two infusions, you will be monitored for a period of time to check for any infusion reactions. If you do well, later monitoring may be shorter.3
Common Side Effects Patients Often Ask About
Like all medicines, DATROWAY can cause side effects, although not everyone gets them. Very common side effects (more than 1 in 10 people) include:4
- Nausea
- Tiredness (fatigue)
- Hair loss (alopecia)
- Constipation
- Vomiting
- Dry eye
- Decreased appetite
- Rash
- Diarrhoea
- Anaemia (low red blood cells)
- Neutropenia (low neutrophils, a type of white blood cell)
- Increased liver enzymes (AST and ALT) in blood tests
Common side effects (up to 1 in 10 people) include:4
- Conjunctivitis (redness and discomfort in the eye)
- Infusion-related reactions such as fever, chills, itching, or rash
- Increased tears
- Dry skin
- Dry mouth
- Itching (pruritus)
- Blepharitis (eyelid inflammation)
- Difficulty breathing (dyspnoea)
- Taste disturbance (dysgeusia)
- Blurred vision
- Leukopenia (low white blood cells)
- Loss of eyelashes (madarosis)
- Light sensitivity
Uncommon side effects include:4
- Visual impairment
Lung-Related Side Effects And Why Doctors Watch Closely
During treatment with DATROWAY, tell your doctor or nurse if you develop cough, shortness of breath, fever, or any new or worsening breathing problems. These may be symptoms of a serious and potentially fatal lung condition called interstitial lung disease (ILD). A history of lung disease may increase the risk of developing ILD, which is why doctors may monitor your lungs during treatment.4
Eye Symptoms And Other Warnings To Report Early
Tell your doctor or nurse early if you develop eye problems during DATROWAY treatment. These may include dry eyes, increased tears, sensitivity to light (photophobia), or vision changes. You may be advised to use preservative-free lubricating eye drops and avoid contact lenses during treatment.4
Allergic reactions, including anaphylaxis, can happen during or shortly after the infusion. If a serious reaction occurs, treatment may be permanently stopped. Also report mouth ulcers, mouth sores, pain, discomfort, or open sores in the mouth, as early treatment and supportive care may be needed.4
How Doctors Monitor You During Treatment
During Datroway treatment, doctors monitor you closely for safety and side effects.
They watch for ILD/pneumonitis (lung inflammation) and check for signs such as breathing-related symptoms. If needed, tests like radiographic imaging may be done, and a pulmonologist may be involved. They also monitor for allergic reactions, including anaphylaxis, especially during or shortly after the infusion.4
Your eyes are another key focus. Doctors watch for keratitis and other eye problems such as dry eyes, increased tears, light sensitivity, or vision changes. You may be referred for ophthalmologic assessment if symptoms appear. They also check for mouth ulcers and sores (stomatitis) and may recommend a non-alcoholic mouthwash, sometimes containing steroids.
Patients with moderate or severe hepatic impairment and severe renal impairment should be monitored carefully during treatment.4
When Doctors Check If DATROWAY Is Working
After the first two infusions, you will be monitored for a period of time to check for any infusion reactions. If you do well, later monitoring may be shorter.3
What Daily Life On DATROWAY Can Feel Like
Daily life on DATROWAY can feel different from person to person, but some things may show up during treatment:5
- You may notice fatigue, which can feel like strong tiredness that is not always relieved by rest.
- Some people also experience nausea, vomiting, constipation, or mouth ulcers (mucositis) that can make eating or drinking uncomfortable.
- There may be eye concerns, such as dry eyes, watery eyes, irritation, blurred vision, or sensitivity to light.
- Some patients develop hair thinning or hair loss (alopecia) on the scalp or body.
- Blood counts can also drop, including white blood cells (leukopenia, lymphopenia, neutropenia) and red blood cells (anemia), which may increase infection risk or cause weakness and shortness of breath.
- It may also affect potassium levels (electrolyte abnormalities) and cause liver toxicity, so regular blood tests and monitoring are part of treatment.
Questions To Ask Before Starting DATROWAY
- Why is DATROWAY being recommended for me?
- What should I expect during treatment days?
- How often will I need infusions or check-ups?
- What side effects should I watch for?
- When should I call the care team?
- Will treatment affect my daily routine or work schedule?
- Are there foods, medicines, or activities I should avoid?
- How will we know if the treatment is working?
Common Mistakes Patients Make During Treatment
- Ignoring new symptoms or waiting too long to report them
- Missing appointments or follow-up visits
- Skipping medicines given to help with side effects
- Not drinking enough fluids or eating regularly
- Pushing through exhaustion without resting
- Starting new medicines or supplements without asking the care team
- Hiding discomfort because they don’t want to “bother” anyone
- Not asking questions when something feels unclear
Conclusion: A Calmer Way To Understand DATROWAY
DATROWAY can come with side effects and regular monitoring, but many parts of treatment are planned and closely managed by your care team. Knowing what to expect, reporting symptoms early, and staying connected with your doctors can help make the process feel more manageable and less overwhelming.
FAQs
What Is DATROWAY Used For
DATROWAY is used for certain advanced cancers, including unresectable or metastatic HR-positive, HER2-negative breast cancer.1
How Does DATROWAY Work
It targets the TROP-2 protein on cancer cells and delivers an anti-cancer medicine directly into those cells.1
Is DATROWAY Chemotherapy Or Targeted Therapy
DATROWAY is a targeted cancer treatment called an antibody-drug conjugate (ADC).1
How Is DATROWAY Given
It is given as an intravenous (IV) infusion in a hospital or clinic by a healthcare professional.3
What Are The Most Common Side Effects Of DATROWAY
Common side effects include nausea, tiredness, hair loss, constipation, vomiting, dry eye, diarrhoea, and low blood counts.4
How Often Do I Need DATROWAY Infusions
DATROWAY is usually given once every 3 weeks, depending on your treatment plan.3
When Should I Call My Doctor While On DATROWAY
Call your doctor if you have breathing problems, fever, serious eye symptoms, allergic reactions, or troubling side effects.4
How Do Doctors Know If DATROWAY Is Working
Doctors monitor your symptoms, treatment response, and overall progress during follow-up visits.3
References
1. Huang J, Huang T, Guo J, Hu K, Zhou H. The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis. Eur J Med Res. 2025;30(1):1265. Published 2025 Dec 29. doi:10.1186/s40001-025-03538-8
2. Bardia A, Krop IE, Kogawa T, et al. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024;42(19):2281-2294. doi:10.1200/JCO.23.01909
3. MedlinePlus. Datopotamab deruxtecan-dlnk injection. MedlinePlus. Updated October 15, 2025. Accessed April 17, 2026.
4. European Medicines Agency. Datroway (datopotamab deruxtecan): summary of product characteristics. European Medicines Agency. Accessed April 17, 2026. https://www.ema.europa.eu/en/documents/product-information/datroway-epar-product-information_en.pdf
5. OncoLink. Datopotamab deruxtecan-dlnk (Datroway®). OncoLink. Reviewed January 29, 2025. Accessed April 17, 2026.
Note:
This information is provided for educational purposes only and is not a substitute for professional medical advice. Datroway should only be taken under the guidance of a qualified healthcare provider. Patients should always consult their doctor or pharmacist for advice on diagnosis, treatment, and medication use, and should not make changes to their prescribed therapy without medical supervision.
Disclaimer:
Rx4U procures prescribed medicines directly from manufacturers or authorized distributors. It does not claim ownership of any trademarks and complies with the provisions of the Trademark Act, 1999, particularly Sections 30 and 30(1) concerning ‘Fair Use’. It solely facilitates access to new launches through named patient import.
